-- Acquisition will allow Codex DNA to expand its commercial BioXp™ system and biofoundry service offerings, reduce raw material costs, and accelerate overall growth strategy -- SAN DIEGO, Nov. 09, ...

Codex DNA to contribute novel synthetic biology-based solutions to stop the spread of a global disease that continues to devastate the citrus industry SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- ...

SAN DIEGO, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced a plan to change its Company name to Telesis Bio.

Codex DNA, fresh off raising $122 million in an initial public stock offering in June, has inked a deal to buy privately held Eton Bioscience — combining two of San Diego’s synthetic biology tools and ...

Todd R. Nelson, Ph.D., has served as the President, Chief Executive Officer and a member of the board of directors of Codex DNA (NASDAQ:DNAY) since July 2018. Prior to joining the company, Dr. Nelson ...

SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the first quarter ended March 31, ...

The company's share price blasted 39% higher because of an exciting new partnership. Under the terms of the deal, the two companies will work together to further develop Codex DNA's BioXP, which its ...

SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced its speaker presentation for the World Vaccine ...

Good afternoon, ladies and gentlemen, and welcome to the Quarter 1 2022 Codex DNA Incorporated earnings conference call. [Operator instructions] I would now likely turn a conference over to your host, ...

Wednesday will go down in history for Codex DNA (NASDAQ: DNAY). The genetics-focused biotech saw its share price rocket 39% higher, thanks to a potentially very lucrative deal with a deep-pocketed ...